Low-Dose Sublingual Ketamine for the Treatment of Raynaud's Phenomenon.
Cureus January 1, 2025 DOI: 10.7759/cureus.77449 via PubMed
Summary
AI-generated from the abstractA woman with primary Raynaud's phenomenon experienced significant symptom improvement while receiving low-dose sublingual ketamine for treatment-resistant depression. Ketamine, an FDA-approved anesthetic, has vasodilatory properties that may enhance blood flow and reduce vascular constriction. This case report suggests that ketamine could be a safe and inexpensive treatment for Raynaud's phenomenon, warranting further research.
Study at a glance
| Characteristics | Case report Peer reviewed |
|---|---|
| Sample size | 1 |
| Population | A woman with primary Raynaud's phenomenon and treatment-resistant depression |
| Intervention | low-dose sublingual ketamine |
| Dose | low-dose |
| Keywords | Anti-inflammatory drugs Cold sensitivity Low-dose ketamine Microvascular perfusion Numbness |
| Key finding | Low-dose sublingual ketamine treatment for depression was associated with significant improvement in Raynaud's phenomenon symptoms. |
Abstract
Raynaud's phenomenon is a vascular disorder characterized by episodic vasospasm of small arteries, primarily affecting the hands and feet. Standard treatment strategies typically include lifestyle modifications to avoid cold exposure and stress, alongside pharmacological interventions aimed at increasing blood flow and reducing vascular constriction. Ketamine, an FDA-approved anesthetic since 1970, exhibits analgesic and vasodilatory properties that may enhance perfusion. This case report describes a woman with primary Raynaud's phenomenon whose symptoms improved significantly during treatment with low-dose sublingual ketamine prescribed for treatment-resistant depression. Further research into the use of this safe and inexpensive medicine as a treatment for Raynaud's phenomenon is recommended.